The first case of acquired hemophilia A associated with SARS‐CoV ‐2 infection-Reference-Cited by-同舟云学术

The first case of acquired hemophilia A associated with SARS‐CoV ‐2 infection

Published:2020-06-03 Issue:8 Volume:95 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Franchini Massimo¹^ORCID,Glingani Claudia¹,De Donno Giuseppe²,Casari Salvatore³,Caruso Beatrice⁴,Terenziani Isabella⁴,Perotti Cesare⁵,Del Fante Claudia⁵,Sartori Filippo⁶,Pagani Mauro⁶

Affiliation:

1. Department of Hematology and Transfusion MedicineCarlo Poma Hospital, ASST Mantova Mantova Italy

2. Respiratory UnitCarlo Poma Hospital, ASST Mantova Mantova Italy

3. Unit of Infectious DiseasesCarlo Poma Hospital, ASST Mantova Mantova Italy

4. LaboratoryCarlo Poma Hospital, ASST Mantova Mantova Italy

5. Immunohaematology and Transfusion Service, Apheresis and Cell Therapy UnitFondazione IRCCS Policlinico San Matteo Pavia Italy

6. Department of MedicineOspedale Destra Secchia, ASST Mantova Mantova Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25865

Reference5 articles.

1. Acquired factor VIII inhibitors

2. A Bruising Loss

3. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

4. Hematological findings and complications of COVID ‐19

5. Immune Thrombocytopenic Purpura in a Patient with Covid-19

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Postpartum Acquired Haemophilia A and Post-partum Life-Threatening Haemorrhage Following COVID-19 Infection: A Case Report;CRESCENT J MED BIOL;2024

2. Inhibitor eradication and treatment for acquired hemophilia A;Expert Review of Hematology;2024-05-09

3. Relapse of Acquired Hemophilia A after COVID-19 Infection;Journal of Nippon Medical School;2023-12-25

4. Hematological Complications in a COVID-19 Patient: A Case Report;Diseases;2023-12-24

5. Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran);Therapies;2023-09